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BRAIN-RELATED COMORBIDITIES IN BOYS AND MEN WITH DUCHENNE MUSCULAR 
DYSTROPHY: A DESCRIPTIVE STUDY 
 
ABSTRACT 
Aim: Duchenne Muscular Dystrophy (DMD) is more than a muscle disease since there is a higher 
prevalence of neuropsychological comorbidities. Similarly, the prevalence of epilepsy is increased. Given 
the nowadays-increasing interest in brain-related comorbidites in DMD, this study aimed to evaluate the 
relationship between DMD, epilepsy, and associated neurodevelopmental disorders in an international 
sample of DMD patients. 
Method: Using a questionnaire-based study we investigated the occurrence of self/by-proxy reported 
brain-related comorbidities in a group of 228 DMD patients. We evaluated the presence of epilepsy and 
other brain-related comorbidities, but also the specific mutation in the dystrophin gene. With respect to 
epilepsy, all individually reported epilepsy cases as based on the questionnaire results including 
information provided on epilepsy treatment, EEG abnormalities, and a description of how a typical seizure 
would look like, were independently and blindly re-assessed by two external paediatric neurologists 
(Cohen’s kappa of 0.85). 
Results: Based on the latter, 18 (7.9%) DMD patients were considered to have epilepsy. In patients with 
both DMD and epilepsy, certain other brain-related comorbidities (i.e. attention deficit hyperactivity 
disorder, obsessive compulsive disorder, anxiety disorders and sleep disorders) were significantly more 
prevalent.  
Conclusion: This study is supportive of a high occurrence of epilepsy and other brain-related comorbidities 
in DMD. Furthermore this study shows for the first time that the frequency of some of these disorders 
appear to be further increased when epilepsy is present next to DMD. As this study is limited by the self/by 
proxy setup and the lack of response rates, future studies should elucidate the true incidence of the 
(triangular) cooccurence between epilepsy, neurodevelopmental deficits, and DMD. 
 
Keywords: Duchenne Muscular Dystrophy, Epilepsy, Seizures, Neurodevelopmental disorders, Sleep 
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1.INTRODUCTION 
Duchenne Muscular Dystrophy (DMD) is an X-linked recessive hereditary disorder caused by a mutation 
in one of the largest genes of the human genome (1) – the dystrophin gene - and is mainly known by its 
severe and progressive physical course. The absence of the dystrophin protein in muscle tissue makes 
muscles prone to degradation, ultimately resulting in cardiac and respiratory impairment in later stages of 
the disease (2, 3), thereby causing premature death (4).  
 The role of the dystrophin protein in DMD is not only limited to muscle function. It has become 
increasingly clear that DMD is more often associated with lower average intellectual abilities – i.e. an IQ of 
one standard deviation below the mean (5)-, learning disabilities like dyslexia (6), and (neuro)behavioural 
disorders such as an increased prevalence of attention deficit (hyperactivity) disorder (ADHD) (7), and 
autism spectrum disorder (ASD) (8-11). Recently, Ricotti and colleagues therefore introduced the term 
“dystrophin associated neurodevelopmental syndrome” (12).  
Although both researchers and clinicians have become somewhat more aware of these potential 
brain-related comorbidities, a straightforward genotype-phenotype correlation has so far not emerged (7, 13, 
14). The hypothesis that distal mutations encompassing the shorter Dp140 and Dp71 isoforms result in more 
profound cognitive impairment (15-18) has been (re-) proposed (12, 14, 19-22). However, a mutation in the full-
length dystrophin protein (Dp427) of mdx mice (the animal model for DMD) was also correlated with some 
extent of cognitive impairment (13). Therefore, it seems rather likely that the cumulative number of 
individual gene products affected by a mutation would be directly correlated with the incidence and 






Abbreviations: AD(H)D, Attention Deficit (Hyperactivity) Disorder; AEDs, Anti-epileptic drugs; ASD, Autism Spectrum Disorder; 
BMD, Becker Muscular Dystrophy; CNS, Central Nervous system; DMD, Duchenne Muscular Dystrophy; EEG, Electro-
encephalogram; GABA, Gamma-aminobutyric acid; ILAE, International League Against Epilepsy; IQ, Intelligence Quotient; OCD, 
Obsessive Compulsive Disorder; TLE, Temporal Lobe Epilepsy 
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In addition, a relationship between (the lack of) dystrophin and hyperexcitation seems to exist (23). 
Three, independent studies demonstrated an increased prevalence of epilepsy in muscular dystrophy 
populations, ranging from 3.1% to 12.3% (24-26). These studies are, however, limited by modest samples 
sizes and by the fact that in one study both DMD and Becker Muscular Dystrophy (BMD) patients were 
included (24). Thus, further international studies are needed to investigate the increased prevalence of 
epilepsy in DMD. Similarly to DMD, neurodevelopmental comorbidities are more prevalent among 
epilepsy patients. Therefore, DMD and epilepsy may share common denominators.  
The primary aim of this observational surveillance study was to (i) specifically examine the 
occurrence of epilepsy in an international population of patients with DMD by means of an online self/by-
proxy report questionnaire. Furthermore, we aimed to (ii) evaluate whether other brain-related 
comorbidities were more frequently reported among DMD patients with epilepsy compared to those 
without. Finally (iii), in order to shed more light on the relatively novel association between epilepsy and 
DMD – including the genetic mutation-, epilepsy characteristics were comprehensively described.  
 
2. MATERIAL & METHODS 
2.1 Patients 
Men and parents of boys from 15 countries (13 Europe, USA, Australia; see table 1 for some of the 
countries and the respective response rates) were invited through the assistance of major national DMD 
charities within each country to participate in the study. The distribution of information on the study was 
carried out by the Dutch Parent Project, a non-profit organization focused entirely on Duchenne and Becker 
muscular dystrophy, and from there sent to the aforementioned different (Duchenne) muscular dystrophy 
parent associations across the world. The different associations, in turn, distributed the information letter to 
the patients and their parents. The ways of information distribution varied among countries: in most 
countries (e.g. Italy, Netherlands) the survey appeared on the community website and in the regular 
newsletter (e.g. the UK), whereas other countries (e.g. Australia, Belgium) put it on their Facebook 
webpage in order to draw attention. Participants were invited to complete a web-based online 
questionnaire. In order to reduce selection-bias, it was explicitly stressed that every boy or parent was 
supposed to complete the questionnaire, also if an epilepsy diagnosis had never been suspected or made.  
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2.2 Questionnaire 
The questionnaire was developed by two paediatric neurologists; one with specific expertise in DMD, the 
other with particular expertise in epilepsy. Both the information letter and the website with the online 
survey itself contained information on how to complete the questionnaire. In order to include an 
international population, native speakers translated the questionnaire into English and Italian. Boys with 
DMD older than 16 years were instructed to complete the questionnaires with assistance from their parents. 
For boys younger than 16, parents were instructed to complete the surveys.  
The online questionnaire consisted of 19 multiple choice and open questions (the original 
questionnaire has been included in the appendix). The first part consisted of general questions such as date 
of birth, nationality, age of DMD diagnosis, medication use, but also the presence of sleep disorders or 
other brain-related comorbidities such as lower intellectual abilities and ADHD (see table 2). The second 
part focussed entirely on whether there has been made an epilepsy diagnosis and on the epilepsy 
characteristics. During the design of the questionnaires the authors classified and defined epilepsy 
according to the most recent International League Against Epilepsy (ILAE) classification (27) and 
implemented it as such in the survey.  
To assist in confirmation and classification of epilepsy the following was asked: a description of a 
typical seizure, age of onset of seizures, seizure types, seizure frequency, EEG characteristics, anti-epileptic 
drugs (AEDs), and response to AEDs. Two external (i.e. not part of the research group) child neurologists 
from Maastricht University Medical Centre with expertise on epilepsy independently inspected the blinded 
questionnaire data of all patients reported to have epilepsy to confirm whether they indeed had epilepsy. 
Concordance between the two observers was calculated by means of Cohen’s Kappa. Any cases for which 
there was a lack of agreement, were reviewed by a third paediatric neurologist, blinded to the responses of 
the other two neurologists. This third and last assessment was decisive for the final allocation of the three 
remaining patients.  
Ethical approval was obtained from the local ethics committee of Kempenhaeghe epilepsy centre, 
Heeze, as part of Maastricht University, the Netherlands.  
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2.3 Data analysis 
General descriptive sample characteristics such as the mean and median age at study entry, and mean of 
DMD diagnosis, were calculated. The results of the questions regarding intelligence, presence of brain-
related comorbidities, and/or learning disorders were transformed in frequencies and subsequently 
expressed as percentages. This was done, first, for the collective DMD population (table 2), and then for the 
epilepsy and the non-epilepsy sub-groups separately (table 4). Difference in proportions between the 
epilepsy and the non-epilepsy group were investigated by means of a Fisher’s exact test (28). For all 





















Country Association Distribution via Addressed (N) Responded (n) Response rate 
Netherlands DPP-NL - Newsletter 
- Website/Facebook 
 





UPPMD - Community website 
- FACES Coordinators  










- Facebook page  N/A n = 16 N/A 
Belgium DPP-B - Facebook page N = 222  n = 20 9.0%  
UK Action 
Duchenne 




- Community website 
N = 594 n = 60 10.6%  
Ireland  - Newsletter N/A n = 5 N/A 
Table 1: Characteristics of participating countries in this questionnaire study. Abbreviations: DPP = Duchenne Parent 
Project, B = Belgium/NL = Netherlands, FACES = Families Advocating, Connecting, Educating, and Supporting (part of 
Parent Project Muscular Dystrophy), UPPMD = United Parent Projects Muscular Dystrophy. 


















269 questionnaires were submitted. Of these, 41 were excluded (36 because of missing information and 5 
because these participants had BMD), resulting in questionnaires on 228 DMD patients being available for 
analyses.   
The mean age of this total group at completion of the questionnaire was 13.25 years (SD = 7.58), 
with a minimum of 0 and a maximum of 32.5 years. The diagnosis DMD was made at a mean age of 3.61  
years (SD = 2.05 years) with a range from 0 to 13 years. Of the patients with DMD, 159 (70.4%) used 
steroids, either currently (93.7%), or in the past (6.3%), yet stopped for multiple reasons, particularly 
because of reported side effects. Deflazocort and prednisone were used almost equally often (48.4% and 
47.8% respectively). Six patients (3.8%) did not know which steroid they were taking, amongst other 
because they participated in trials. 
                                                        
* For men only, 7.3% for all anxiety disorders among men and women 
^ This number reflects the prevalence of a current major depressive disorder; 12 month prevalence was 5.28, life time prevalence 
13.2% 
Comorbidity n       DMD (%) Normal population (%) 
Cognitive level                                                          
Serious impairment (IQ<70) 
Moderate impairment (70 < IQ < 85) 
Normal (85 < IQ < 115) 
Higher level (IQ > 115) 





















 No learning disability 
 Reading disability 
 Arithmetic disability 
 Reading and arithmetic disability 
























 Neuropsychiatric diagnosis 
 ADHD 
 Autism spectrum disorder (ASD) 
 Obsessive compulsive disorder (OCD) 
 Anxiety disorder  

























Table 2: Overview of the reported (brain-related) comorbidities in the collective DMD sample studied (N = 228), and in comparison 
to the normal population as based on the literature. 
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 The IQ level was not known in 53 patients (23.2%). Forty patients (17.5 %) turned out to have 
impaired intellectual abilities (IQ < 85). Patients and/or parents reported other learning- and cognitive 
disorders, including dysgraphia, concentration difficulties, language and speech (processing) difficulties, 
memory difficulties, general developmental delay, and problems with information processing. Additional 
characteristics on self/by-proxy reported brain-related comorbidities (e.g. ASD and learning disorders) in 
this DMD cohort are described in table 2. As patients and parents participated anonymously in this survey, 
additional data on the sample characteristics and the characteristics of the non-responders were not 
available. 
Thirty-two subjects with possible epilepsy were initially identified. However, reasons for 
exclusion from the eventual epilepsy group were insufficient information provided and/or not meeting the 
criteria for epilepsy (n = 10) and the presence of (solely) febrile seizures (n = 4). Thus, there were 18 
subjects with physician confirmed epilepsy (Cohen’s Kappa, 0.850, SE = 0.102), and as such epilepsy was 
present in 7.9% (95% CI 4.9-12.4%) of the patients that participated in this study. Eleven boys or men were 
currently having epilepsy (61.1%), whereas 7 boys suffered from it in the past (38.9%). All epilepsy 
patients, including additional epilepsy-related characteristics, are shown in table 5. The age of onset ranged 
from 0 to 16 years (mean 9.24 years, SD = 4.76 years). EEG’s were made in 17 patients (94.4%) and 
revealed abnormalities in 13 DMD patients (76.5%). Seizure frequency varied from less than one per year 
(42.3%) to almost daily (14.2%); the remaining patients (43.5%) had seizures varying from less than once a 
week to more than once per year. AEDs, however, had been able to control most of the reported seizures as 
8 boys (53.8%) reported to be seizure free now, 5 patients (38.5%) reported a 50% reduction, whereas in 
one patient no change was noted. AED effectiveness was unknown in 4 patients (27.8%). One patient 
without epilepsy used sodium valproate (Depakine) for the control of migraine. Information on seizure 
types and AEDs has been displayed in table 3. Three patients with epilepsy were not on AEDs - of whom 
two not yet - which was in one case related to the (very) recent seizure-onset and in one case due to the 
very young age. Corticosteroids, as part of DMD treatment, were used in 11 of the DMD patients with 
epilepsy (61.2%).  
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Seizure type Subtype n % 




Tonic seizures 0 0.0 
Tonic-clonic seizures 6 31,6 
Myoclonic seizures 0 0.0 
Focal Focal seizures 6 31,6 
Total 19 100 
AED Carbamazepine 1 4.5 
Ethosuccumide 1 4.5 
Lamotrigine 4 18.2 
Levetiracetam 4 18.2 
None 4 18.2 
Oxcarbazemapine 1 4.5 
Phenobarbital 1 4.5 
Topiramate 1 4.5 
Valproate 4 18.2 
Zonisamide 1 4.5 
Total* 22 100 
Table 3: Collective seizure type- and AED frequencies in a sample of DMD patients with epilepsy. Note: also AED’s for 
patients who are seizure-free now, yet were used in the past are listed in this table. For individual (i.e. per patient) 
characteristics, see table 5.  * The fact that more AED’s are reported, compared to patients, can be clarified by the fact that 
four patients used two AEDs. Similarly, some patients had multiple seizure types (again, see table 5).  
 
Six boys/men (35.3%) with epilepsy were cognitively impaired (5 patients with moderate 
impairment, i.e. an IQ below 85, and 1 with serious impairment, i.e. an IQ of below 70), eight patients 
(47.1 %) had an average IQ – i.e. between 85 and 115 -, and three patients (17.6%) had an IQ higher than 
115 (for one patient the IQ-score was not known). This did not differ significantly from the DMD group 
without epilepsy (N = 210; the IQ was unknown for 52 patients in this subgroup): 21.5% with intellectual 
impairment (24 patients with moderate impairment and 10 with serious impairment), 56.9% with a normal 
IQ, and 21.5% with an IQ > 115 (depicted in table 5, together with the respective p-values). From table 4 it 
can furthermore be concluded that all neuropsychiatric comorbidities and learning disorders (here: 
dyscalculia and dyslexia) were reported in both groups. The comorbidities ADHD, OCD, anxiety-, and 
sleep disorders were significantly more prevalent in the epilepsy subgroup.   
Although mutations were reported in a relatively small proportion of patients, the following was 
reported on the type and location of the mutation in the dystrophin gene within the epilepsy cohort: in 3 
patients (16.7%) the mutation was not known, 6 patients (33.3%) had a mutation upstream of exon 45, 
whereas in 3 patients (16.7%) the mutation was located, at least partly, between exon 51 and exon 62. In 
the 6 remaining patients (33.3%), the mutation was located between intron 44 and 51 (as indicated by 
Dp140* in table 5). None of the patients with epilepsy had a mutation downstream of exon 63; 
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consequently in none of the epilepsy patients Dp71 was affected, nor were all three isoforms involved in 
any patient. The consequences of the abovementioned on the expression of the different dystrophin 
isoforms have been summarized in table 5 (per patient).   
 
Epilepsy (n = 18) Non-Epilepsy (n = 210) P-value 
Intelligence                            Intelligence 
Impairment (IQ < 85) 
Normal intelligence (IQ: 85-115) 





Impairment (IQ < 85) 
Normal intelligence (IQ: 85-115) 

















































Other disorders Other disorders 
Sleep disorder 33.3% Sleep disorder 5.2% 0.001 
 
 
Table 4: Reported brain-related comorbidities in DMD patients with and without epilepsy. Patients with DMD and besides 
epilepsy report on generally lower intellectual capabilities (however, a significant difference could not be detected) and 
significantly more behavioural co-morbidities such as ADHD and OCD. Next, they report more frequently on anxiety 
disorders. Learning, specifically with regards to reading and mathematics, appeared not to result statistically more often in 
problems when a concomitant epilepsy diagnosis was present. Finally, a significant association between the two neurological 
disorders studied in relation to DMD in this study (i.e. epilepsy and sleep disorders) was observed. *P-values were considered 
significant at an alpha < 0.05. 
 
















IQ  NPD/ 
Sleep  
LD 
1 12 yr.  AUS - - - 
 










N < 85 N N 
2 
 


















N >115 N N 












N AVG N N 
4 7 yr.  SA Dp427 
 









N < 85 ADH/
ASD 
N 


















P AVG N N 
















P AVG ADH/ Y 
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7 14 yr.  USA Dp427, 
Dp140* 






N AVG sleep Y 
8 13 yr.  ITA Dp427,  
Dp140* 
6 yr.  Absence
Tonic-
clonic 









1 yr.  ITA Dp427,  
Dp140* 
1 yr. Absence <1x/year Abn None 
 
- N AVG N N 
10 
 

















13 yr.  USA Dp427,  
Dp140 
7 yr.  Focal, 
Tonic-
clonic 


























13 15 yr.  USA Dp427,  
Dp140* 















13 yr.  NZE Dp427, 
Dp140* 
9 yr.  Absence Used to be 
almost 
daily 



















22 yr.  NL Dp427,  
Dp140* 
5 yr.  Absence Used to be 
<1x/year 





- - Dp427 9 yr.  Focal, 
Tonic-
clonic 








14 yr.  USA Dp427 
 




N <85 N Y 
18 
 
20 yr.  USA Dp427,  
Dp140 
10 yr.  Idiopath
pro-  
voked 









Table 5: Characteristics for all DMD patients with epilepsy, both in present and past, including reported cognitive abilities 
and concomitant diagnosis with neurodevelopmental disorders. Abbreviations: Abn. = abnormal, Anx = Anxiety disorder, 
ADH/ = Attention Deficit Hyperactivity Disorder, ASD = Autism Spectrum Disorder, AUS = Australia, AVG = Average (85 < 
IQ < 115), Depr = Depressive disorder, ITA = Italy, IQ = Intelligence Quotient,  LD = learning disorder, N = No/Negative, NL 
= Netherlands, Nor. = normal,  NPD = Neuropsychiatric disorder, NZE = New-Zealand, P = positive,  SA = South- Africa, 
sleep = sleep disorder, TLE = Temporal Lobe Epilepsy, USA = United States of America, VNS = vagal nerve stimulation, Y = 
yes (here: presence of learning disorder), yr. = years, - = missing, * = not with certainty known whether Dp140 is affected due 
to the unpredictable effect of mutations between intron 44 and exon 51 on Dp140 expression (see discussion). 
 
4. DISCUSSION 
This study supports an increased occurrence of brain related comorbidities in DMD, particularly with 
regards to epilepsy. Furthermore, and more importantly, this study is the first to show that some of these 
disorders (i.e. ADHD, OCD, anxiety, and sleep disorders) are significantly more often present in DMD 
patients additionally having epilepsy. This is a new finding, which may have important clinical 
implications.  
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4.1 Epilepsy is more often reported in DMD populations 
The population studied here is the largest group of DMD patients so far evaluated in relation to epilepsy. 
Almost 8% of the DMD patients and parents reported to have a diagnosis of epilepsy. This is substantially 
higher than in the general paediatric population (0,5 -1%) (32), and comparable to the prevalence found by a 
recent Italian study with a different set-up (26). Ten other patients who reported to suffer from epilepsy 
were, based on the strict criteria used, excluded from the epilepsy group since their answers were lacking 
important clinical data in order to confirm the presence of epilepsy. Therefore, the occurrence of epilepsy 
might even be higher in this group of boys with DMD, even though the ascertained number of 7.9% is in 
keeping with the published literature. Furthermore, absence seizures were the most frequently reported 
seizure type among this cohort. Consequently, the concomitant diagnosis of epilepsy in DMD patients, 
which is not well known in clinical practice, might be easily overlooked or confused with neuropsychiatric 
disorders such as AD(H)D. This diagnostic overshadowing is an important (new) aspect in DMD.   
Apart from that, we identified 6 DMD patients with provoked seizures; i.e. two patients in whom 
the seizures were precipitated by video/computer screens (these were included in the epilepsy group as they 
were considered to have epilepsy by both child neurologists as based on the clinical information provided) 
and the four patients with febrile seizures (who were excluded from the epilepsy group). Furthermore one 
of the excluded five BMD patients was considered to have Rolandic epilepsy without EEG abnormalities 
and treated with Depakine, which resulted in seizure remission. Finally, one mother (a carrier of the 
mutation in the DMD gene) reported to have generalized epilepsy, whereas her son did not have seizures. 
 
4.2 Additional brain related comorbidities in DMD in relation to epilepsy 
Our study supports the increased prevalence of neurodevelopmental comorbidities in DMD (table 2) as 
compared to the general paediatric population (5-7, 9, 11, 34-36). Especially ASD and OCD were again, more 
frequently reported compared to the general population (9). This is interesting, since epilepsy is also 
frequently associated with neurodevelopmental impairment (37, 38). Indeed, epilepsy diagnosed in addition to 
DMD was associated with an increased occurrence of neurobehavioral comorbidities such as ADHD and 
OCD as table 4 illustrates. Remarkably, DMD patients diagnosed with epilepsy also reported significantly 
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more often on an anxiety disorder. This is in line with previous studies demonstrating that epileptic seizures 
are associated with anxiety disorders that furthermore affect mortality, seizure status, and quality of life (39). 
Unsurprisingly, in boys and men with both DMD and epilepsy, a third of the patients reported to have sleep 
problems, compared to only 5.2 percent in the non-epilepsy DMD group. It has been suggested that the 
abovementioned disruption of the neuronal GABA architecture due to the lack of Dp427 in the brain may 
partly explain the sleep disorders seen in DMD (13). Whether this may possibly be exacerbated by 
(poor)seizure control, number or effectiveness of AEDs, or perhaps due to indirect, potential consequences 
of seizures is unclear and deserves attention in future research. This association is however important given 
the fact that sleep problems influence quality of life - but also behaviour, cognition, and even seizure 
control – negatively (40).  
 
4.3 Mutations and isoforms in relation to epilepsy in DMD 
Within this cohort, in all patients with epilepsy and with the known mutation (n =15), the mutation was 
located upstream of exon 62, thereby either affecting both Dp427 and Dp140 or Dp427 alone. This is 
similar to the recent findings by Pane and colleagues (26). The full-length isoform, Dp427, was thus affected 
in all patients. This could be attributed to the fact that the region between exon 2 and 20 and exon 45-53 are 
two common deletion hotspots (41) causing the absence of Dp427m (muscle). This also results in the 
absence of brain Dp427c (cerebrum), which is known to anchor GABA-A (gamma-aminobutyric acid) 
receptors post-synaptically (42). We recently demonstrated a Dp427 up-regulation in temporal lobe epilepsy 
patients, possibly revealing a dystrophin-mediated counteracting mechanism towards hyperexcitable brain 
networks by means of exerting more inhibitory GABA input (43). Conversely, since such mechanisms are, 
defective in the brains of DMD patients, this may clarify seizure threshold alterations, hence making boys 
with DMD theoretically more prone to develop epilepsy.  
Six patients reported to have a mutation between exon 45 and 51. Since these exons constitute the 
5’untranslated region of Dp140, it is unpredictable whether Dp140 is expressed in these patients (18). Dp140 
has so far not been linked to hyperexcitation from a theoretical nor practical perspective, not least since it 
seems to be rather developmentally regulated (44, 45) - notwithstanding its possible relationship with 
cognitive deficits (19). 
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None of the epilepsy patients reported to have a distal mutation that would furthermore affect 
Dp71, and hence all three isoforms. The lack of a distal mutation in the dystrophin gene is possibly the 
consequence of the fact that these mutations are generally rare (12), as also reflected by the fact that in only 
four of the patients within the total cohort studied here and with known mutation (n = 168), Dp71 was 
expected to be missing as based on mutation analyses. Thus, in contrast to the cognitive problems, where it 
has been proposed that the distal mutations – particularly including Dp71 (14, 20, 21) - would have a more 
profound effect on cognitive deficits, this may not necessarily be the case for epilepsy. This is intriguing 
given the fact that a deficiency in Dp71, albeit theoretically, may have a profound effect on epileptogenesis 
by different mechanisms involving water-channels, potassium channels, and the blood-brain barrier (23). 
Therefore once again, the rarity of this mutation should be considered and stressed, which - in combination 
with the small sub-group of patients with both DMD and epilepsy – also impeded a meaningful analysis. 
 
4.4 Study limitations and future perspectives 
We chose the self-report questionnaire in order to acquire a large and global group of DMD patients by 
making use of relatively novel means such as social media aiming to reach more people within the target 
audience. A limitation of the latter is the lack of insight in response rates, which were only known for the 
Italian, Belgian, and Dutch population, yet were difficult to estimate. Furthermore, these known response 
rates were low, as can be seen in table 1. Therefore, the true numbers reported for epilepsy may have been 
overestimated given the risk of (selection-) bias. We tried to reduce this bias by stressing that every DMD 
patient (and/or their parents) should complete the questionnaire.  
Although the percentage of patients with ASD and OCD in our study was similar compared to 
previous studies, ADHD was less frequently reported (i.e. reports in literature demonstrated rates of 11.7% 
in one study (9) and 20-30% in multiple other studies (7, 22, 46)). Concerning the data on IQ scores it remains 
true that differences between the epilepsy and the non-epilepsy group are to some extent difficult to 
compare because of missing data (approximately 25% in the non-epilepsy group). These missing data may 
also partly clarify why our population is not per se representative with regards to the occurrence of learning 
or intellectual disabilities as only five percent had intellectual impairment (i.e. IQ scores < 70), whilst this 
was found to be 34.8% in the largest meta-analysis hitherto performed (5). This suggests there might be a 
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population bias in the cohort studied here. Similarly, internalizing problems (anxiety and depression) might 
be under-represented in this study population as Ricotti et al. identified 24% to have such problems (12). 
Banihani and colleagues found anxiety in 27%, (22), whereas one other study identified 51% of the patients 
to have a depressed mood (46). These differences could additionally be partly attributed to the self/by-proxy 
nature of this study. 
As mentioned, the accuracy of using a self/parent report for collecting information on brain-related 
comorbidities or mutations - of which the data was furthermore only known for a small proportion of 
patients and should thus be interpreted with caution - can be questioned. However with regards to the 
primary outcome of this study, i.e. epilepsy, subsequent assessment by two external neurologists as based 
on additional objective information provided was performed in order to enhance the accuracy of the 
numbers presented here.  
 Since it was not feasible to translate the survey into all the languages of the countries to which an 
invitation to participate was sent, the three languages expected to be most relevant to our sample were 
chosen. However, possible language problems among people in other countries, might have also 
contributed to selection bias.  As patients filled out the questionnaire anonymously, we were not able to 
contact patients, or their clinicians, for additional information.  
More preclinical research is required in order to understand the pathophysiological relationship 
between (a lack of) dystrophin and epilepsy. In addition, cross sectional population based studies should 
confirm the existence of a possible triangular relationship between DMD, epilepsy, and 
neurodevelopmental disorders. Furthermore, long-term longitudinal studies should evaluate the 
consequences of epilepsy and AED usage (including polytherapy) for boys and men with both DMD and 
epilepsy. More research on this association between DMD and epilepsy, its cause and consequences for 




The results from this survey reveal that patients with DMD and their parents more frequently report on 
epilepsy and other brain related-comorbdities, which is supportive on an increased prevalence of epilepsy 
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in DMD. As clinicians may not be aware of this, a possible diagnosis of epilepsy may be easily 
overshadowed by DMD and/or its spectrum of neurodevelopmental features. This is particularly true, as 
sleep disorders, AD(H)D, OCD, and anxiety disorders appear to occur more frequent among boys with both 
DMD and epilepsy. Moreover, since such comorbidities are also more often observed in epilepsy, a 
common underlying pathological mechanism (e.g. the absence of dystrophin) may be considered. More 
research is needed to examine the existence of a potential syndrome or triad including DMD, epilepsy, and 
neurodevelopmental disorders, in other words whether epilepsy could possibly be added to the recently 
proposed “dystrophin associated neurodevelopmental syndrome”.  
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